Eli Lilly & Co. will set up a S$42 million ($31 million) digital health innovation hub in Singapore, expanding its research ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

[Photo/Agencies] US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in Suzhou, Jiangsu province, that will enable it to increase ...

Researchers from Duality Biologics (Suzhou) Co. Ltd. presented the discovery and preclinical characterization of DB-1314, a ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Eli Lilly (NYSE: LLY) stock tanked after the company reported third-quarter results on Wednesday, Oct. 30. The report it issued before the opening bell was more than a little problematic.

Sensorineural hearing loss (SNHL) is the most common type of hearing loss, caused by damage to the inner ear (cochlea) or the auditory nerve pathways. Aging is the most significant risk factor for ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...